SUPPORT-AF IV: Supporting use of AC through provider prompting about oral anticoagulation therapy for AF clinical trial study protocol

Background: Six million Americans suffer from atrial fibrillation (AF), a heart rhythm abnormality that significantly increases the risk of stroke. AF is responsible for 15% of ischemic strokes, which lead to permanent disability in 60% of cases and death in up to 20%. Anticoagulation (AC) is the ma...

Full description

Bibliographic Details
Main Authors: Jay Patel, BS, Hammad Sadiq, BS, John Catanzaro, MD, FHRS, Sybil Crawford, PhD, Adam Wright, PhD, Gordon Manning, MD, Jeroan Allison, MD, MSc, Kathleen Mazor, EdD, David McManus, MD, MSc, FHRS, Alok Kapoor, MD, MSc
Format: Article
Language:English
Published: Elsevier 2021-08-01
Series:Cardiovascular Digital Health Journal
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2666693621000591
id doaj-10fe455e3c904ae59edd7df2194597e9
record_format Article
spelling doaj-10fe455e3c904ae59edd7df2194597e92021-08-14T04:31:57ZengElsevierCardiovascular Digital Health Journal2666-69362021-08-0124222230SUPPORT-AF IV: Supporting use of AC through provider prompting about oral anticoagulation therapy for AF clinical trial study protocolJay Patel, BS0Hammad Sadiq, BS1John Catanzaro, MD, FHRS2Sybil Crawford, PhD3Adam Wright, PhD4Gordon Manning, MD5Jeroan Allison, MD, MSc6Kathleen Mazor, EdD7David McManus, MD, MSc, FHRS8Alok Kapoor, MD, MSc9Department of Medicine, University of Massachusetts Medical School, Worcester, MassachusettsDepartment of Medicine, University of Massachusetts Medical School, Worcester, MassachusettsDepartment of Medicine, University of Florida College of Medicine, Jacksonville, FloridaDepartment of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts; Division of Preventive and Behavioral Medicine, University of Massachusetts Medical School, Worcester, MassachusettsDepartment of Biomedical Informatics, University of Vanderbilt School of Medicine, Nashville, TennesseeDepartment of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts; University of Massachusetts Memorial Health Care, Worcester, MassachusettsUniversity of Massachusetts Memorial Health Care, Worcester, Massachusetts; Department of Population and Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MassachusettsDepartment of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts; University of Massachusetts Memorial Health Care, Worcester, Massachusetts; Meyers Primary Care Institute, A Joint Endeavor of University of Massachusetts Medical School, Reliant Medical Group, and Fallon Health, Worcester, MassachusettsDepartment of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts; University of Massachusetts Memorial Health Care, Worcester, MassachusettsDepartment of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts; University of Massachusetts Memorial Health Care, Worcester, Massachusetts; Address reprint requests and correspondence: Dr Alok Kapoor, Biotech One, Suite 100, University of Massachusetts Medical School, 365 Plantation St, Worcester, MA 01605.Background: Six million Americans suffer from atrial fibrillation (AF), a heart rhythm abnormality that significantly increases the risk of stroke. AF is responsible for 15% of ischemic strokes, which lead to permanent disability in 60% of cases and death in up to 20%. Anticoagulation (AC) is the mainstay for stroke prevention in patients with AF. Despite guidelines recommending AC for patients, up to half of eligible patients are not on AC. Clinical decision support tools in the electronic health record (EHR) can help bridge the disparity in AC prescription for patients with AF. Objective: To enhance and assess the effectiveness of our previous rule-based alert on AC initiation and persistence in a diverse patient population from UMass-Memorial Medical Center and University of Florida at Jacksonville. Methods/Results: Using the EHR, we will track AC initiation and persistence. We will interview both patients and providers to determine a measure of satisfaction with AC management. We will track digital crumbs to better understand the alert’s mechanism of effect and further add enhancements. These enhancements will be used to refine the alert and aid in developing an implementation toolkit to facilitate use of the alert at other health systems. Conclusion: If the number of AC starts, the likelihood of persisting on AC, and the frequency alert use are found to be higher among intervention vs control providers, we believe such findings will confirm our hypothesis on the effectiveness of our alert.http://www.sciencedirect.com/science/article/pii/S2666693621000591AnticoagulationAtrial fibrillationClinical decision supportClinical trialsElectronic medical records
collection DOAJ
language English
format Article
sources DOAJ
author Jay Patel, BS
Hammad Sadiq, BS
John Catanzaro, MD, FHRS
Sybil Crawford, PhD
Adam Wright, PhD
Gordon Manning, MD
Jeroan Allison, MD, MSc
Kathleen Mazor, EdD
David McManus, MD, MSc, FHRS
Alok Kapoor, MD, MSc
spellingShingle Jay Patel, BS
Hammad Sadiq, BS
John Catanzaro, MD, FHRS
Sybil Crawford, PhD
Adam Wright, PhD
Gordon Manning, MD
Jeroan Allison, MD, MSc
Kathleen Mazor, EdD
David McManus, MD, MSc, FHRS
Alok Kapoor, MD, MSc
SUPPORT-AF IV: Supporting use of AC through provider prompting about oral anticoagulation therapy for AF clinical trial study protocol
Cardiovascular Digital Health Journal
Anticoagulation
Atrial fibrillation
Clinical decision support
Clinical trials
Electronic medical records
author_facet Jay Patel, BS
Hammad Sadiq, BS
John Catanzaro, MD, FHRS
Sybil Crawford, PhD
Adam Wright, PhD
Gordon Manning, MD
Jeroan Allison, MD, MSc
Kathleen Mazor, EdD
David McManus, MD, MSc, FHRS
Alok Kapoor, MD, MSc
author_sort Jay Patel, BS
title SUPPORT-AF IV: Supporting use of AC through provider prompting about oral anticoagulation therapy for AF clinical trial study protocol
title_short SUPPORT-AF IV: Supporting use of AC through provider prompting about oral anticoagulation therapy for AF clinical trial study protocol
title_full SUPPORT-AF IV: Supporting use of AC through provider prompting about oral anticoagulation therapy for AF clinical trial study protocol
title_fullStr SUPPORT-AF IV: Supporting use of AC through provider prompting about oral anticoagulation therapy for AF clinical trial study protocol
title_full_unstemmed SUPPORT-AF IV: Supporting use of AC through provider prompting about oral anticoagulation therapy for AF clinical trial study protocol
title_sort support-af iv: supporting use of ac through provider prompting about oral anticoagulation therapy for af clinical trial study protocol
publisher Elsevier
series Cardiovascular Digital Health Journal
issn 2666-6936
publishDate 2021-08-01
description Background: Six million Americans suffer from atrial fibrillation (AF), a heart rhythm abnormality that significantly increases the risk of stroke. AF is responsible for 15% of ischemic strokes, which lead to permanent disability in 60% of cases and death in up to 20%. Anticoagulation (AC) is the mainstay for stroke prevention in patients with AF. Despite guidelines recommending AC for patients, up to half of eligible patients are not on AC. Clinical decision support tools in the electronic health record (EHR) can help bridge the disparity in AC prescription for patients with AF. Objective: To enhance and assess the effectiveness of our previous rule-based alert on AC initiation and persistence in a diverse patient population from UMass-Memorial Medical Center and University of Florida at Jacksonville. Methods/Results: Using the EHR, we will track AC initiation and persistence. We will interview both patients and providers to determine a measure of satisfaction with AC management. We will track digital crumbs to better understand the alert’s mechanism of effect and further add enhancements. These enhancements will be used to refine the alert and aid in developing an implementation toolkit to facilitate use of the alert at other health systems. Conclusion: If the number of AC starts, the likelihood of persisting on AC, and the frequency alert use are found to be higher among intervention vs control providers, we believe such findings will confirm our hypothesis on the effectiveness of our alert.
topic Anticoagulation
Atrial fibrillation
Clinical decision support
Clinical trials
Electronic medical records
url http://www.sciencedirect.com/science/article/pii/S2666693621000591
work_keys_str_mv AT jaypatelbs supportafivsupportinguseofacthroughproviderpromptingaboutoralanticoagulationtherapyforafclinicaltrialstudyprotocol
AT hammadsadiqbs supportafivsupportinguseofacthroughproviderpromptingaboutoralanticoagulationtherapyforafclinicaltrialstudyprotocol
AT johncatanzaromdfhrs supportafivsupportinguseofacthroughproviderpromptingaboutoralanticoagulationtherapyforafclinicaltrialstudyprotocol
AT sybilcrawfordphd supportafivsupportinguseofacthroughproviderpromptingaboutoralanticoagulationtherapyforafclinicaltrialstudyprotocol
AT adamwrightphd supportafivsupportinguseofacthroughproviderpromptingaboutoralanticoagulationtherapyforafclinicaltrialstudyprotocol
AT gordonmanningmd supportafivsupportinguseofacthroughproviderpromptingaboutoralanticoagulationtherapyforafclinicaltrialstudyprotocol
AT jeroanallisonmdmsc supportafivsupportinguseofacthroughproviderpromptingaboutoralanticoagulationtherapyforafclinicaltrialstudyprotocol
AT kathleenmazoredd supportafivsupportinguseofacthroughproviderpromptingaboutoralanticoagulationtherapyforafclinicaltrialstudyprotocol
AT davidmcmanusmdmscfhrs supportafivsupportinguseofacthroughproviderpromptingaboutoralanticoagulationtherapyforafclinicaltrialstudyprotocol
AT alokkapoormdmsc supportafivsupportinguseofacthroughproviderpromptingaboutoralanticoagulationtherapyforafclinicaltrialstudyprotocol
_version_ 1721207608873844736